LAMBERT, Juliette |
AVAJAK, NCT05198960: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms |
|
|
| Recruiting | 3 | 1308 | Europe | Direct Oral Anticoagulants, Low-dose aspirin | University Hospital, Brest | Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients | 07/27 | 07/27 | | |
OGILAR, NCT06022003: Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia |
|
|
| Recruiting | 2 | 33 | Europe | AzaCITIDine Oral Tablet, Onureg, CC-486, Xospata, Gilteritinib | French Innovative Leukemia Organisation, Acute Leukemia French Association | AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation, FLT3-ITD | 10/25 | 04/26 | | |
| Recruiting | 2 | 50 | Europe | Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata | Centre Antoine Lacassagne, Acute Leukemia French Association | AML | 03/27 | 03/27 | | |
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics |
|
|
| Recruiting | 2 | 210 | Europe | Cytarabine and Idarubicin, CPX-315 | Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association | Acute Myeloid Leukemia | 10/27 | 10/27 | | |
SALMA, NCT05580861: Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment |
|
|
| Recruiting | 1/2 | 64 | Europe | Sulfasalazine | Assistance Publique - Hôpitaux de Paris | Acute Myeloid Leukemia | 11/25 | 12/26 | | |
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | N/A | 2500 | Europe | | Acute Leukemia French Association | Acute Myeloid Leukemia (AML) | 04/32 | 04/46 | | |
VENAZA, NCT06263387: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine |
|
|
| Recruiting | N/A | 230 | Europe | | French Innovative Leukemia Organisation, Acute Leukemia French Association | AML, Adult | 12/24 | 03/25 | | |